Science & Technology
Novel multivalent PSMA-targeted taxane-conjugates for bone metastases in prostate cancer
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R43CA306207-01
Award Ceiling
$353K
Award Floor
$353K
Close Date
Aug 31, 2026
169 days leftTotal Funding
$353K
Expected Awards
1
Posted Date
Sep 24, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-1R43CA306207-01
Description
SBIR Phase Phase I award: "Novel multivalent PSMA-targeted taxane-conjugates for bone metastases in prostate cancer" awarded to PARAMITA THERAPEUTICS, INC. in SAN DIEGO, California. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $353,009. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses, Socially/economically disadvantaged
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.